Skip to main content

Table 1 Baseline clinical characteristic of the 156 patients with cerebral malaria in both treatment arms on admission.

From: Mannitol as adjunct therapy for childhood cerebral malaria in Uganda: A randomized clinical trial

Variable

Placebo

N = 80

Mannitol

N = 76

P value

Female

42(52.5%)

34(44.7%)

0.33

Fever

79(98.8)

76 (100%)

0.33

Convulsions

79(98.8%)

75(98.7%)

0.97

Duration of coma

7.0 (IQR3.5–12.0)

6.0 (5.0–12.0)

0.79

Blantyre coma score 1/5

13(16.2%)

10(13.2%)

0.59

Abnormal fundoscopic changesa

28(35.0%))

16(21.1%)

0.53

Papilloedema

3(3.8%)

5(6.6%)

0.42

Sodium – mmol/l (SD)

133.8 (4.2)

130.9 (14.8)

0.09

Hb – g/dl (SD)

7.1 (1.8)

7.1 (1.9)

0.98

Parasite density/μL (IQR)

37000(5390–115760)

58860(12390–284590)

0.05

  1. IQR Inter Quartile Range
  2. aAbnormal fundoscopic changes (congested retinal veins, blurred disc margins, papilloema, retinal haemorrhages) indicative of raised intracranial pressure